1362-P: Eligibility for GLP-1 Receptor Agonists for Obesity across 91 Countries

Journal article

S. G. K. Yoo, M. Theilmann, Megan W. Lam, Dessie Tien, M. Marcus, N. Chandiwana, Justine I Davies, Mohammed K. Ali, David Flood, Jen Manne-Goehler
Diabetes, 2025

Semantic Scholar DOI

Cite

APA Click to copy
Yoo, S. G. K., Theilmann, M., Lam, M. W., Tien, D., Marcus, M., Chandiwana, N., … Manne-Goehler, J. (2025). 1362-P: Eligibility for GLP-1 Receptor Agonists for Obesity across 91 Countries. Diabetes.

Chicago/Turabian Click to copy
Yoo, S. G. K., M. Theilmann, Megan W. Lam, Dessie Tien, M. Marcus, N. Chandiwana, Justine I Davies, Mohammed K. Ali, David Flood, and Jen Manne-Goehler. “1362-P: Eligibility for GLP-1 Receptor Agonists for Obesity across 91 Countries.” Diabetes (2025).

MLA Click to copy
Yoo, S. G. K., et al. “1362-P: Eligibility for GLP-1 Receptor Agonists for Obesity across 91 Countries.” Diabetes, 2025.

BibTeX Click to copy

@article{s2025a,
  title = {1362-P: Eligibility for GLP-1 Receptor Agonists for Obesity across 91 Countries},
  year = {2025},
  journal = {Diabetes},
  author = {Yoo, S. G. K. and Theilmann, M. and Lam, Megan W. and Tien, Dessie and Marcus, M. and Chandiwana, N. and Davies, Justine I and Ali, Mohammed K. and Flood, David and Manne-Goehler, Jen}
}

Abstract

Introduction and Objective: GLP-1 receptor agonists (GLP-1 RAs) may reshape obesity management & diabetes prevention. However, there is scant evidence about global populations who may benefit from them. Here we evaluate eligibility for GLP-1 RAs across 91 countries. Methods: We use the Global Health and Population Project on Access to Cardiometabolic Care (HPACC) to estimate eligibility for GLP-1 RAs among 773,513 adults age 25-64 years from population-weighted, nationally representative surveys. Eligible participants had a BMI ≥30 kg/m2 or BMI ≥27 kg/m2 + ≥1 weight-related comorbidity as measured in the survey. We report eligibility by age, sex at birth, household wealth quintile, & country income group per the World Bank. Results: Overall, 27.6% (95% CI: 27.1 - 28.2) of adults [equivalent to 750,287,482 individuals] are eligible for GLP-1 RA overall; 65.9% qualify based on BMI alone and there were no sex differences. Differences by age & wealth quintile are shown in Fig. 1. Eligibility differs starkly by national-level wealth [high income: 44.0% (42.4-45.6), upper-middle: 33.5% (32.3-34.7), lower-middle: 21.4% (21.0-21.9), low: 11.5% (10.8-12.4)]. Conclusion: Over 750 million people globally are eligible for GLP-1 RAs, 34.1% of whom have comorbidities. Though eligibility is greatest in older and wealthier sub-groups, nearly 20% of those in the poorest wealth quintiles and youngest age groups may also benefit from this therapy, raising the importance of equity in global GLP-1 RA access.

S.K. Yoo: None. M. Theilmann: None. M.W. Lam: None. D. Tien: None. M. Marcus: None. N.C. Chandiwana: Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. J. Davies: None. M.K. Ali: Advisory Panel; Eli Lilly and Company. D. Flood: None. J. Manne-Goehler: None.